Company to host fourth quarter conference call and webcast today at 8 a.m. EDT / 12 p.m. GMT LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial […]
Author: Ken Dropiewski
Valbiotis Publishes Its 2022 Annual Results and Provides an Update on Its Strategic Roadmap
A cash position of more than €20 million at the end of 2022, which provides the Company financial visibility until the end of the first half of 2024; A decisive year on the clinical front with the results of the Phase II/III REVERSE-IT study on TOTUM•63, expected before the end […]
FIRE1 Raises $25 Million to Revolutionize Heart Failure Home Monitoring
DUBLIN–(BUSINESS WIRE)–FIRE1, today announced the close of a $25 million financing round led by new investors Andera Partners and Novo Holdings, with participation and ongoing support from existing investors Gilde Healthcare, Gimv, the Ireland Strategic Investment Fund, Lightstone Ventures, Medtronic, New Enterprise Associates and Seventure Partners. The financing provides FIRE1 […]
A Conversation on Revolutionizing Vascular Surgery + Challenging the Medical Field with Dr. Frank J. Veith
Dr. Frank J. Veith and McDermott + Bull Partner Ken Dropiewski talk about the challenges in getting the medical field to adopt new procedures, the state of the vascular techniques he introduced to the industry, as well as an insider’s look into the field with his new book, The Medical […]
HeartBeam Announces Acquisition of LIVMOR Assets
Extends HeartBeam’s Reach with FDA-cleared Halo+™ Atrial Fibrillation Detection System and Physician-prescribed Integrated Patient Care Platform SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, today announced the strategic acquisition of substantially […]
Acesion Pharma announces positive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint achieved
First-in-class SK channel inhibition proof of mechanism achieved First new approach to treating Atrial Fibrillation for 20 years COPENHAGEN, Denmark, March 14, 2023 /PRNewswire/ — Acesion Pharma (“Acesion”), the biotech pioneering first-in-class novel therapies for Atrial Fibrillation (“AF”), the most common cardiac arrhythmia, today announced positive data from its Phase 2 trial of […]
Philips and Gibraltar Health Authority announce 16-year strategic partnership, transforming patient imaging and cardiac care at St Bernard’s Hospital
March 07, 2023 For the first time, patients will no longer need to travel abroad for treatment of acute cardiac diseases, as the Gibraltar Health Authority prepares to provide local coronary angiography and angioplasty services in a new interventional cardiac suite Amsterdam, the Netherlands and Gibraltar – Royal Philips (NYSE: PHG, AEX: […]
Shockwave Medical Announces U.S. Launch of New Peripheral IVL Catheter
Shockwave L⁶ Provides Physicians with Larger-Diameter Catheters to Expand Potential Treatment of Peripheral Vessels SANTA CLARA, Calif., March 14, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the full U.S. commercial availability […]
LeMaitre to Go Direct in Thailand
BURLINGTON, Mass., March 14, 2023 (GLOBE NEWSWIRE) — LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants and services, today announced that it has signed a definitive agreement to buy out its Thai distributor, Prompt Serve, for $688,000. In 2022 Prompt Serve purchased $950,000 of LeMaitre devices which […]
Karolinska Development’s portfolio company AnaCardio’s founder publishes article that supports development of heart failure drug candidate AC01
STOCKHOLM, SWEDEN March 14, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the founder of its portfolio company AnaCardio, Professor Lars Lund, has published an article on a heart failure study in the scientific journal European Heart Journal. The study’s publication reinforces the company’s efforts to develop a […]



